三阴性乳腺癌新辅助治疗策略及其分子分型的研究进展
Research Progress on New Adjuvant Treatment Strategies and Molecular Typing of Triple-Negative Breast Cancer
摘要: 三阴性乳腺癌(TNBC)是一种缺乏雌激素受体、孕激素受体和人表皮生长因子受体-2表达的乳腺癌亚型，以其侵袭性高、预后较差及治疗选择有限而被广泛关注。新辅助治疗(NAT)作为TNBC治疗策略中的重要组成部分，对于缩小肿瘤、提高手术成功率及探索疾病生物行为具有重要意义。本文综述了TNBC的新辅助治疗策略及其分子分型的最新研究进展，评估了多项临床试验和实验研究结果，揭示了不同治疗策略对疗效的影响。研究显示，针对特定分子标志的新辅助治疗能够在一定程度上提高TNBC患者的病理完全缓解率(pCR)，进而改善长期生存率。
Abstract: Triple-negative breast cancer (TNBC) is a subtype of breast cancer that lacks the expression of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2, and has attracted extensive attention due to its high aggressiveness, poor prognosis and limited treatment options. Neoadjuvant therapy (NAT), as an important part of TNBC treatment strategy, is of great significance for reducing the tumor, improving the success rate of surgery and exploring the biological behavior of the disease. This article reviews the latest research progress of neoadjuvant therapy strategies and molecular typing of TNBC, evaluates the results of multiple clinical trials and experimental studies, and reveals the influence of different treatment strategies on efficacy. Studies have shown that neoadjuvant therapy targeting specific molecular markers can improve pathological complete response rate (pCR) in TNBC patients to a certain extent, thereby improving long-term survival.
文章引用：廖丽萍, 黄大元, 吴涛. 三阴性乳腺癌新辅助治疗策略及其分子分型的研究进展[J]. 临床医学进展, 2024, 14(7): 130-139. https://doi.org/10.12677/acm.2024.1471991

参考文献

[1] Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. [Google Scholar] [CrossRef] [PubMed]
[2] Zhang, W., Bai, Y., Sun, C., Lv, Z. and Wang, S. (2022) Racial and Regional Disparities of Triple Negative Breast Cancer Incidence Rates in the United States: An Analysis of 2011-2019 NPCR and SEER Incidence Data. Frontiers in Public Health, 10, Article 1058722. [Google Scholar] [CrossRef] [PubMed]
[3] Yin, L., Duan, J., Bian, X. and Yu, S. (2020) Triple-negative Breast Cancer Molecular Subtyping and Treatment Progress. Breast Cancer Research, 22, Article No. 61. [Google Scholar] [CrossRef] [PubMed]
[4] Garrido-Castro, A.C., Lin, N.U. and Polyak, K. (2019) Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment. Cancer Discovery, 9, 176-198. [Google Scholar] [CrossRef] [PubMed]
[5] Bareche, Y., Venet, D., Ignatiadis, M., Aftimos, P., Piccart, M., Rothe, F., et al. (2018) Unravelling Triple-Negative Breast Cancer Molecular Heterogeneity Using an Integrative Multiomic Analysis. Annals of Oncology, 29, 895-902. [Google Scholar] [CrossRef] [PubMed]
[6] Lehmann, B.D., Bauer, J.A., Chen, X., Sanders, M.E., Chakravarthy, A.B., Shyr, Y., et al. (2011) Identification of Human Triple-Negative Breast Cancer Subtypes and Preclinical Models for Selection of Targeted Therapies. Journal of Clinical Investigation, 121, 2750-2767. [Google Scholar] [CrossRef] [PubMed]
[7] Lehmann, B.D., Jovanović, B., Chen, X., Estrada, M.V., Johnson, K.N., Shyr, Y., et al. (2016) Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection. PLOS ONE, 11, e0157368. [Google Scholar] [CrossRef] [PubMed]
[8] Burstein, M.D., Tsimelzon, A., Poage, G.M., Covington, K.R., Contreras, A., Fuqua, S.A.W., et al. (2015) Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer. Clinical Cancer Research, 21, 1688-1698. [Google Scholar] [CrossRef] [PubMed]
[9] Jiang, Y.Z., Ma, D., Suo, C., et al. (2019) Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies. Cancer Cell, 35, 428-440.E5.
[10] Zhao, S., Ma, D., Xiao, Y., Li, X., Ma, J., Zhang, H., et al. (2020) Molecular Subtyping of Triple-Negative Breast Cancers by Immunohistochemistry: Molecular Basis and Clinical Relevance. The Oncologist, 25, e1481-e1491. [Google Scholar] [CrossRef] [PubMed]
[11] Garutti, M., Pelizzari, G., Bartoletti, M., Malfatti, M.C., Gerratana, L., Tell, G., et al. (2019) Platinum Salts in Patients with Breast Cancer: A Focus on Predictive Factors. International Journal of Molecular Sciences, 20, Article 3390. [Google Scholar] [CrossRef] [PubMed]
[12] Torrisi, R., Zuradelli, M., Agostinetto, E., Masci, G., Losurdo, A., De Sanctis, R., et al. (2019) Platinum Salts in the Treatment of Brca-Associated Breast Cancer: A True Targeted Chemotherapy? Critical Reviews in Oncology/Hematology, 135, 66-75. [Google Scholar] [CrossRef] [PubMed]
[13] Takamizawa, S., Ishiki, H., Shimoi, T., Shimizu, M. and Satomi, E. (2020) Neoadjuvant Cisplatin in BRCA Carriers with HER2-Negative Breast Cancer. Journal of Clinical Oncology, 38, 2699-2700. [Google Scholar] [CrossRef] [PubMed]
[14] Jin, J., Zhang, W., Ji, W., Yang, F. and Guan, X. (2017) Predictive Biomarkers for Triple Negative Breast Cancer Treated with Platinum-Based Chemotherapy. Cancer Biology & Therapy, 18, 369-378. [Google Scholar] [CrossRef] [PubMed]
[15] Chen, Y., Wang, X., Du, F., Yue, J., Si, Y., Zhao, X., et al. (2023) Association between Homologous Recombination Deficiency and Outcomes with Platinum and Platinum-Free Chemotherapy in Patients with Triple-Negative Breast Cancer. Cancer Biology & Medicine, 20, 155-168. [Google Scholar] [CrossRef] [PubMed]
[16] von Minckwitz, G., Schneeweiss, A., Loibl, S., Salat, C., Denkert, C., Rezai, M., et al. (2014) Neoadjuvant Carboplatin in Patients with Triple-Negative and HER2-Positive Early Breast Cancer (GeparSixto; GBG 66): A Randomised Phase 2 Trial. The Lancet Oncology, 15, 747-756. [Google Scholar] [CrossRef] [PubMed]
[17] Sikov, W.M., Berry, D.A., Perou, C.M., et al. (2015) Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-Per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance). Journal of Clinical Oncology, 33, 13-21.
[18] Rugo, H.S., Olopade, O.I., DeMichele, A., Yau, C., van ’t Veer, L.J., Buxton, M.B., et al. (2016) Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer. New England Journal of Medicine, 375, 23-34. [Google Scholar] [CrossRef] [PubMed]
[19] Li, Z., Zhang, Z., Cao, X., Feng, Y. and Ren, S. (2020) Platinum-Based Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis. Journal of International Medical Research, 48, No. 10. [Google Scholar] [CrossRef] [PubMed]
[20] Filho, O.M., Stover, D.G., Asad, S., Ansell, P.J., Watson, M., Loibl, S., et al. (2021) Association of Immunophenotype with Pathologic Complete Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer. JAMA Oncology, 7, 603-608. [Google Scholar] [CrossRef] [PubMed]
[21] Hahnen, E., Lederer, B., Hauke, J., Loibl, S., Kröber, S., Schneeweiss, A., et al. (2017) Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer. JAMA Oncology, 3, 1378-1385. [Google Scholar] [CrossRef] [PubMed]
[22] Shepherd, J.H., Ballman, K., Polley, M.C., Campbell, J.D., Fan, C., Selitsky, S., et al. (2022) CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival after Neoadjuvant Chemotherapy with or without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer. Journal of Clinical Oncology, 40, 1323-1334. [Google Scholar] [CrossRef] [PubMed]
[23] Geyer, C.E., Sikov, W.M., Huober, J., Rugo, H.S., Wolmark, N., O’Shaughnessy, J., et al. (2022) Long-term Efficacy and Safety of Addition of Carboplatin with or without Veliparib to Standard Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer: 4-Year Follow-Up Data from Brightness, a Randomized Phase III Trial. Annals of Oncology, 33, 384-394. [Google Scholar] [CrossRef] [PubMed]
[24] Zhao, F., Shen, G., Dong, Q., Xin, Y., Huo, X., Wang, M., et al. (2022) Impact of Platinum-Based Chemotherapy on the Prognosis of Early Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis. Clinical and Experimental Medicine, 23, 2025-2040. [Google Scholar] [CrossRef] [PubMed]
[25] Dixon-Douglas, J. and Loi, S. (2023) Immunotherapy in Early-Stage Triple-Negative Breast Cancer: Where Are We Now and Where Are We Headed? Current Treatment Options in Oncology, 24, 1004-1020. [Google Scholar] [CrossRef] [PubMed]
[26] Wong, R.S., Ong, R.J. and Lim, J.S. (2023) Immune Checkpoint Inhibitors in Breast Cancer: Development, Mechanisms of Resistance and Potential Management Strategies. Cancer Drug Resistance, 6, 768-787. [Google Scholar] [CrossRef] [PubMed]
[27] Schmid, P., Cortes, J., Dent, R., Pusztai, L., McArthur, H., Kümmel, S., et al. (2022) Event-Free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer. New England Journal of Medicine, 386, 556-567. [Google Scholar] [CrossRef] [PubMed]
[28] Mittendorf, E.A., Zhang, H., Barrios, C.H., Saji, S., Jung, K.H., Hegg, R., et al. (2020) Neoadjuvant Atezolizumab in Combination with Sequential Nab-Paclitaxel and Anthracycline-Based Chemotherapy versus Placebo and Chemotherapy in Patients with Early-Stage Triple-Negative Breast Cancer (IMpassion031): A Randomised, Double-Blind, Phase 3 Trial. The Lancet, 396, 1090-1100. [Google Scholar] [CrossRef] [PubMed]
[29] Loibl, S., Schneeweiss, A., Huober, J., Braun, M., Rey, J., Blohmer, J., et al. (2022) Neoadjuvant Durvalumab Improves Survival in Early Triple-Negative Breast Cancer Independent of Pathological Complete Response. Annals of Oncology, 33, 1149-1158. [Google Scholar] [CrossRef] [PubMed]
[30] Cunha, M.T., Gouveia, M.C., Neto, F.L., Testa, L., Hoff, P.M., de Azambuja, E., et al. (2023) Long-Term Outcomes of Neoadjuvant Immunotherapy plus Chemotherapy in Patients with Early-Stage Triple-Negative Breast Cancer: An Extracted Individual Patient Data and Trial-Level Meta-Analysis. British Journal of Cancer, 130, 242-250. [Google Scholar] [CrossRef] [PubMed]
[31] Sharma, P., Stecklein, S.R., Yoder, R., Staley, J.M., Schwensen, K., O’Dea, A., et al. (2024) Clinical and Biomarker Findings of Neoadjuvant Pembrolizumab and Carboplatin plus Docetaxel in Triple-Negative Breast Cancer. JAMA Oncology, 10, 227-235. [Google Scholar] [CrossRef] [PubMed]
[32] Pusztai, L., Yau, C., Wolf, D.M., Han, H.S., Du, L., Wallace, A.M., et al. (2021) Durvalumab with Olaparib and Paclitaxel for High-Risk HER2-Negative Stage II/III Breast Cancer: Results from the Adaptively Randomized I-SPY2 Trial. Cancer Cell, 39, 989-998.E5. [Google Scholar] [CrossRef] [PubMed]
[33] Vinayak, S., Tolaney, S.M., Schwartzberg, L., Mita, M., McCann, G., Tan, A.R., et al. (2019) Open-Label Clinical Trial of Niraparib Combined with Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer. JAMA Oncology, 5, 1132-1140. [Google Scholar] [CrossRef] [PubMed]
[34] Jain, P. (2023) Unlocking Therapeutic Potential of Poly(Adenosine Diphosphate Ribose) Polymerase (PARP) Inhibitors in Metastatic Breast Cancer with BRCA Gene Mutations: A Narrative Review. Cureus, 15, e46405. [Google Scholar] [CrossRef] [PubMed]
[35] Exman, P., Barroso-Sousa, R. and Tolaney, S.M. (2019) Evidence to Date: Talazoparib in the Treatment of Breast Cancer. OncoTargets and Therapy, 12, 5177-5187. [Google Scholar] [CrossRef] [PubMed]
[36] Robson, M.E., Tung, N., Conte, P., Im, S., Senkus, E., Xu, B., et al. (2019) Olympiad Final Overall Survival and Tolerability Results: Olaparib versus Chemotherapy Treatment of Physician’s Choice in Patients with a Germline BRCA Mutation and HER2-Negative Metastatic Breast Cancer. Annals of Oncology, 30, 558-566. [Google Scholar] [CrossRef] [PubMed]
[37] Litton, J.K., Hurvitz, S.A., Mina, L.A., Rugo, H.S., Lee, K., Gonçalves, A., et al. (2020) Talazoparib versus Chemotherapy in Patients with Germline BRCA1/2-Mutated HER2-Negative Advanced Breast Cancer: Final Overall Survival Results from the EMBRACA Trial. Annals of Oncology, 31, 1526-1535. [Google Scholar] [CrossRef] [PubMed]
[38] Miricescu, D., Totan, A., Stanescu-Spinu, I., Badoiu, S.C., Stefani, C. and Greabu, M. (2020) PI3K/AKT/mTOR Signaling Pathway in Breast Cancer: From Molecular Landscape to Clinical Aspects. International Journal of Molecular Sciences, 22, Article 173. [Google Scholar] [CrossRef] [PubMed]
[39] Dong, C., Wu, J., Chen, Y., Nie, J. and Chen, C. (2021) Activation of PI3K/AKT/mTOR Pathway Causes Drug Resistance in Breast Cancer. Frontiers in Pharmacology, 12, Article 628690. [Google Scholar] [CrossRef] [PubMed]
[40] Alves, C.L. and Ditzel, H.J. (2023) Drugging the PI3K/AKT/mTOR Pathway in ER+ Breast Cancer. International Journal of Molecular Sciences, 24, Article 4522. [Google Scholar] [CrossRef] [PubMed]
[41] Kalimutho, M., Parsons, K., Mittal, D., López, J.A., Srihari, S. and Khanna, K.K. (2015) Targeted Therapies for Triple-Negative Breast Cancer: Combating a Stubborn Disease. Trends in Pharmacological Sciences, 36, 822-846. [Google Scholar] [CrossRef] [PubMed]
[42] Oliveira, M., Saura, C., Nuciforo, P., Calvo, I., Andersen, J., Passos-Coelho, J.L., et al. (2019) Fairlane, a Double-Blind Placebo-Controlled Randomized Phase II Trial of Neoadjuvant Ipatasertib plus Paclitaxel for Early Triple-Negative Breast Cancer. Annals of Oncology, 30, 1289-1297. [Google Scholar] [CrossRef] [PubMed]
[43] Niemeier, L.A., Dabbs, D.J., Beriwal, S., Striebel, J.M. and Bhargava, R. (2010) Androgen Receptor in Breast Cancer: Expression in Estrogen Receptor-Positive Tumors and in Estrogen Receptor-Negative Tumors with Apocrine Differentiation. Modern Pathology, 23, 205-212. [Google Scholar] [CrossRef] [PubMed]
[44] Thike, A.A., Yong-Zheng Chong, L., Cheok, P.Y., Li, H.H., Wai-Cheong Yip, G., Huat Bay, B., et al. (2014) Loss of Androgen Receptor Expression Predicts Early Recurrence in Triple-Negative and Basal-Like Breast Cancer. Modern Pathology, 27, 352-360. [Google Scholar] [CrossRef] [PubMed]
[45] Jiang, Y., Liu, Y., Xiao, Y., Hu, X., Jiang, L., Zuo, W., et al. (2020) Molecular Subtyping and Genomic Profiling Expand Precision Medicine in Refractory Metastatic Triple-Negative Breast Cancer: The Future Trial. Cell Research, 31, 178-186. [Google Scholar] [CrossRef] [PubMed]
[46] Yang, C., Zhang, J., Zhang, Y., Ji, F., Chen, Y., Zhu, T., et al. (2022) Low-dose Apatinib Combined with Neoadjuvant Chemotherapy in the Treatment of Early-Stage Triple-Negative Breast Cancer (LANCET): A Single-Center, Single-Arm, Phase II Trial. Therapeutic Advances in Medical Oncology, 14. [Google Scholar] [CrossRef] [PubMed]
[47] Spring, L.M., Tolaney, S.M., Fell, G., Bossuyt, V., Abelman, R.O., Wu, B., et al. (2024) Response-Guided Neoadjuvant Sacituzumab Govitecan for Localized Triple-Negative Breast Cancer: Results from the Neostar Trial. Annals of Oncology, 35, 293-301. [Google Scholar] [CrossRef] [PubMed]

为你推荐